Largiadèr CR - Search Results

1

CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients.

Lesche D, Sigurdardottir V, Setoud R, Oberhänsli M, Carrel T, Fiedler GM, Largiadèr CR, Mohacsi P, Sistonen J. Lesche D, et al. Among authors: largiader cr. Ther Drug Monit. 2014 Dec;36(6):710-5. doi: 10.1097/FTD.0000000000000080. Ther Drug Monit. 2014. PMID: 24739669 Free article.

2

A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy.

Sistonen J, Smith C, Fu YK, Largiadèr CR. Sistonen J, et al. Among authors: largiader cr. Clin Chim Acta. 2012 Dec 24;414:109-11. doi: 10.1016/j.cca.2012.08.015. Epub 2012 Aug 23. Clin Chim Acta. 2012. PMID: 22935545

3

Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS in monitoring the 5-fluorouracil plasma levels in cancer patients.

Büchel B, Sistonen J, Joerger M, Aebi Y, Schürch S, Largiadèr CR. Büchel B, et al. Among authors: largiader cr. Clin Chem Lab Med. 2013 Aug;51(8):1681-8. doi: 10.1515/cclm-2012-0641. Clin Chem Lab Med. 2013. PMID: 23412878 Free article.

4

Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.

Sistonen J, Büchel B, Froehlich TK, Kummer D, Fontana S, Joerger M, van Kuilenburg AB, Largiadèr CR. Sistonen J, et al. Among authors: largiader cr. Pharmacogenomics. 2014 Sep;15(13):1653-66. doi: 10.2217/pgs.14.126. Pharmacogenomics. 2014. PMID: 25410891

5

Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy.

Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiadèr CR. Amstutz U, et al. Among authors: largiader cr. Clin Cancer Res. 2015 May 1;21(9):2038-44. doi: 10.1158/1078-0432.CCR-14-2817. Epub 2015 Feb 5. Clin Cancer Res. 2015. PMID: 25655103

6

Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.

Kummer D, Froehlich TK, Joerger M, Aebi S, Sistonen J, Amstutz U, Largiadèr CR. Kummer D, et al. Among authors: largiader cr. Pharmacogenomics. 2015;16(12):1367-77. doi: 10.2217/pgs.15.81. Epub 2015 Aug 5. Pharmacogenomics. 2015. PMID: 26244261

7

Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation.

Lesche D, Sigurdardottir V, Setoud R, Englberger L, Fiedler GM, Largiadèr CR, Mohacsi P, Sistonen J. Lesche D, et al. Among authors: largiader cr. Clin Transplant. 2015 Dec;29(12):1213-20. doi: 10.1111/ctr.12653. Epub 2015 Nov 23. Clin Transplant. 2015. PMID: 26458301

8

Association of the Intestinal Microbiome with the Development of Neovascular Age-Related Macular Degeneration.

Zinkernagel MS, Zysset-Burri DC, Keller I, Berger LE, Leichtle AB, Largiadèr CR, Fiedler GM, Wolf S. Zinkernagel MS, et al. Among authors: largiader cr. Sci Rep. 2017 Jan 17;7:40826. doi: 10.1038/srep40826. Sci Rep. 2017. PMID: 28094305 Free PMC article.

9

Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement.

Lesche D, Sigurdardottir V, Leichtle AB, Nakas CT, Christians U, Englberger L, Fiedler M, Largiadèr CR, Mohacsi P, Sistonen J. Lesche D, et al. Among authors: largiader cr. Metabolomics. 2017 Nov 25;14(1):3. doi: 10.1007/s11306-017-1294-8. Metabolomics. 2017. PMID: 30830337 Free article.

10

Metabolomics by UHPLC-MS: benefits provided by complementary use of Q-TOF and QQQ for pathway profiling.

Freiburghaus K, Largiadèr CR, Stettler C, Fiedler GM, Bally L, Bovet C. Freiburghaus K, et al. Among authors: largiader cr. Metabolomics. 2019 Aug 28;15(9):120. doi: 10.1007/s11306-019-1585-3. Metabolomics. 2019. PMID: 31463683 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

103 results

Search Page

Filters